ZA881512B - Synergistic interplay of lymphokines and double-stranded rnas - Google Patents

Synergistic interplay of lymphokines and double-stranded rnas

Info

Publication number
ZA881512B
ZA881512B ZA881512A ZA881512A ZA881512B ZA 881512 B ZA881512 B ZA 881512B ZA 881512 A ZA881512 A ZA 881512A ZA 881512 A ZA881512 A ZA 881512A ZA 881512 B ZA881512 B ZA 881512B
Authority
ZA
South Africa
Prior art keywords
lymphokines
dsrna
human
double
disorders
Prior art date
Application number
ZA881512A
Other languages
English (en)
Inventor
William A Carter
A Carter William
Original Assignee
Hem Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hem Res Inc filed Critical Hem Res Inc
Publication of ZA881512B publication Critical patent/ZA881512B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA881512A 1987-03-03 1988-03-03 Synergistic interplay of lymphokines and double-stranded rnas ZA881512B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2136887A 1987-03-03 1987-03-03

Publications (1)

Publication Number Publication Date
ZA881512B true ZA881512B (en) 1988-11-30

Family

ID=21803798

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA881512A ZA881512B (en) 1987-03-03 1988-03-03 Synergistic interplay of lymphokines and double-stranded rnas

Country Status (19)

Country Link
EP (1) EP0281380B1 (da)
JP (1) JPH0713024B2 (da)
KR (1) KR960008009B1 (da)
CN (1) CN1054509C (da)
AT (1) ATE130760T1 (da)
AU (2) AU1256588A (da)
CA (1) CA1336810C (da)
DE (1) DE3854726T2 (da)
DK (1) DK113188A (da)
ES (1) ES2082749T3 (da)
FI (1) FI880961A7 (da)
IE (1) IE75895B1 (da)
IL (1) IL85603A (da)
NO (1) NO880946L (da)
NZ (1) NZ223720A (da)
PH (1) PH24467A (da)
PT (1) PT86879B (da)
RU (1) RU1836103C (da)
ZA (1) ZA881512B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA881639B (en) * 1987-03-23 1989-02-22 Hem Res Inc Treatment of human viral infection by dsrna combined with viral inhibitors
DE69021791T2 (de) * 1989-06-30 1996-05-02 American Cyanamid Co Verwendung eines phagozytise-aktievierenden Stoffes : LPS oder IL-2 zur Herstellung eines Arzneimittels zur Behandlung von Staphylococcus-aureus-Infektionen bei Kühen.
FR2768345B1 (fr) * 1997-09-17 2001-05-04 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale, notamment d'une hepatite virale
FR2766715B1 (fr) * 1997-08-04 2001-02-16 Scras Produit comprenant au moins de l'arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique simultanee, separee ou etalee dans le temps, dans le traitement d'une maladie virale
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
FR2768344B1 (fr) * 1997-08-26 2001-02-16 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
BRPI9908967B1 (pt) 1998-03-20 2017-05-30 Benitec Australia Ltd processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
US10392444B2 (en) 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380200D1 (en) * 1982-09-16 1989-08-24 William Alvin Carter Anti-proliferative action of dsnras on tumor cells
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)

Also Published As

Publication number Publication date
PT86879A (pt) 1988-04-01
PH24467A (en) 1990-07-18
DK113188A (da) 1988-09-04
FI880961L (fi) 1988-09-04
NO880946L (no) 1988-09-05
ES2082749T3 (es) 1996-04-01
IE75895B1 (en) 1997-09-24
CN1032296A (zh) 1989-04-12
RU1836103C (ru) 1993-08-23
EP0281380A2 (en) 1988-09-07
AU1256588A (en) 1988-09-01
DE3854726T2 (de) 1996-07-25
IE880588L (en) 1988-09-03
CA1336810C (en) 1995-08-29
CN1054509C (zh) 2000-07-19
ATE130760T1 (de) 1995-12-15
DE3854726D1 (de) 1996-01-11
KR880010776A (ko) 1988-10-24
NZ223720A (en) 1991-07-26
JPH0713024B2 (ja) 1995-02-15
AU1618992A (en) 1992-08-06
FI880961A0 (fi) 1988-03-02
FI880961A7 (fi) 1988-09-04
IL85603A (en) 1993-05-13
NO880946D0 (no) 1988-03-03
JPS63295514A (ja) 1988-12-01
IL85603A0 (en) 1988-08-31
DK113188D0 (da) 1988-03-02
EP0281380B1 (en) 1995-11-29
KR960008009B1 (ko) 1996-06-19
EP0281380A3 (en) 1989-09-27
PT86879B (pt) 1992-05-29

Similar Documents

Publication Publication Date Title
IL85603A0 (en) Synergistic interplay of lymphokines and double-stranded rnas
ATE73347T1 (de) Antivirales immunotherapeutisches mittel und dessen herstellung.
PH23333A (en) Treatment of human viral infections by dsrna combined with viral inhibitors
NZ226005A (en) Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof
UA29429C2 (uk) Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини
EP0306347A3 (en) Diagnosis and treatment of double-stranded rna deficiency states
BG100599A (en) Antiviral form and therapeutical method
BR9007741A (pt) Protecao contra estados de choque subsequentes a lesoes por rnas de duplo filamento
ES2036526T3 (es) Composiciones de interferon.
EP0325018A3 (en) Rnase l inhibitor as a marker for virus infections
EP0294538A3 (en) Use of nigericin in the treatment of viral diseases
EP0240274A3 (en) Avermectins as growth promotant agents
DE69106877D1 (de) Aus blaualgen hergestellte biologisch aktive verbindungen.
MY111746A (en) Therapeutic nucleosides.
EP1013763A4 (en) INTERLEUKIN 18 AND INTERLEUKIN 18-CONVERTASE OF THE DOG, DNA MOLECULES CODING THEREOF, PROCESS FOR THE PRODUCTION OF INTERLEUKIN 18 AND MEANS FOR THE TREATMENT OF DISEASES OF THE IMMUNE SYSTEM IN DOGS.
GR3024236T3 (en) Use of leukoregulin for the treatment of animals infected with an envelope-virus
Kohl Additive effects of acyclovir and immune transfer in neonatal herpes simplex virus infection in mice
EP0668771A4 (en) TREATMENT OF AUTOIMMUNE DISEASES BY TOLERANCE IN CELLS, TISSUES AND ORGANS.
SU1727820A1 (ru) Способ стимул ции сперматогенеза у быков
ES2007094A6 (es) Procedimiento para la preparacion de 3 -c- ciano-2,3 -didesoxinucleosido.
FR2047884A1 (en) Anti-leukopenic partially-lysed thymus - extract
JO1708B1 (en) The use of trinitrobenzene or cochineal acid in the treatment of cancer or genital diseases
ZA881639B (en) Treatment of human viral infection by dsrna combined with viral inhibitors